Green Alpha Advisors, LLC Bio N Tech Se Transaction History

Green Alpha Advisors, LLC

$122 Million
Q2 2024

A detailed history of Green Alpha Advisors, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 3,996 shares of BNTX stock, worth $472,726. This represents 0.26% of its overall portfolio holdings.

Number of Shares

3,996

Previous 5,819 31.33%

Holding current value

$472,726

Previous $536,000 40.11%

% of portfolio

0.26%

Previous 0.4%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $146,496 - $187,532	-1,823 Reduced 31.33%	3,996 $321,000
Q1 2024 Apr 09, 2024	BUY	$88.96 - $112.35 $59,247 - $74,825	666 Added 12.92%	5,819 $536,000
Q4 2023 Jan 04, 2024	SELL	$90.91 - $112.75 $5,090 - $6,314	-56 Reduced 1.08%	5,153 $543,000
Q3 2023 Oct 10, 2023	BUY	$98.5 - $125.08 $248,121 - $315,076	2,519 Added 93.64%	5,209 $565,000
Q2 2023 Jul 06, 2023	BUY	$102.58 - $129.66 $9,437 - $11,928	92 Added 3.54%	2,690 $290,000
Q1 2023 Apr 06, 2023	SELL	$122.57 - $153.67 $99,036 - $124,165	-808 Reduced 23.72%	2,598 $323,000
Q4 2022 Jan 12, 2023	BUY	$118.43 - $186.05 $11,487 - $18,046	97 Added 2.93%	3,406 $0
Q3 2022 Oct 14, 2022	BUY	$127.65 - $183.11 $57,953 - $83,131	454 Added 15.9%	3,309 $446,000
Q2 2022 Jul 08, 2022	SELL	$123.25 - $186.24 $141,860 - $214,362	-1,151 Reduced 28.73%	2,855 $426,000
Q1 2022 Apr 19, 2022	BUY	$126.25 - $231.85 $55,045 - $101,086	436 Added 12.21%	4,006 $683,000
Q4 2021 Jan 12, 2022	BUY	$216.64 - $362.52 $14,731 - $24,651	68 Added 1.94%	3,570 $920,000
Q3 2021 Oct 12, 2021	BUY	$205.93 - $447.23 $5,766 - $12,522	28 Added 0.81%	3,502 $956,000
Q2 2021 Jul 22, 2021	BUY	$113.32 - $241.49 $393,673 - $838,936	3,474 New	3,474 $778,000

Others Institutions Holding BNTX

# of Institutions

328

Shares Held

40.6M

Call Options Held

845K

Put Options Held

1.23M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.

Account

Green Alpha Advisors, LLC Bio N Tech Se Transaction History